Vascular Deformation Mapping (VDM) for Automated, 3D Assessment of Thoracic Aortic Aneurysm

项目摘要 胸主动脉瘤（TAA）是一种慢性疾病，具有发展危及生命的风险 并发症如主动脉夹层（即，主动脉壁的分层）和破裂（即，透壁 撕裂）。TAA的主要管理目标是早期识别主动脉扩张， 在主动脉达到预测未来并发症的尺寸之前替换它。据估计， 仅美国的患者就符合基于当前指南的主动脉成像监测标准。 需要改进成像监测策略，以解决TAA的健康和经济影响。 然而，CT图像标准主动脉直径测量的可靠性仍然很低。 在这个建议中，我们将利用最近开发的图像分析技术，血管变形映射 (VDM)，对TAA患者的主动脉生长进行半自动三维评估 接受影像监视这种新颖的方法利用先进的计算机分析技术， 充分利用现代CT扫描仪生成的丰富、高分辨率的体积数据， 更全面和可靠的评估主动脉生长。VDM能够显著提高 TAA生长分析的速度和可靠性，促进主动脉生长评估之间的沟通 放射科医生，护理提供者和患者，并产生新的疾病进展的生物标志物， 用于改善患者管理决策，并最终改善患者结局。 在这项赠款努力中，我们建议通过我们与以下方面的密切合作来实现该项目的目标： 密歇根大学（UM）和Imbio，LLC研究人员。因此，这一快速通道提案的具体目标 我将开发一个商业的VDM软件应用程序，包括产品测试和数据采集 FDA 510（k）申请。

PROJECT SUMMARY Thoracic aortic aneurysm (TAA) is a chronic condition that carries the risk of developing life-threatening complications such as aortic dissection (i.e., delamination of the aortic wall) and rupture (i.e., transmural tearing). The primary management objectives for TAA are to identify aortic dilation early and to surgically replace the aorta before it reaches a size that predicts future complications. It is estimated that 3 million patients in the US alone would meet criteria for aortic imaging surveillance based on current guidelines. Improved imaging surveillance strategies are needed to address the health and economic impacts of TAA. However, the reliability of standard aortic diameter measurements from CT images remains low. In this proposal, we will utilize a recently developed image analysis technique, Vascular Deformation Mapping (VDM), to perform semi-automated, three-dimensional assessment of aortic growth in patients with TAA undergoing imaging surveillance. This novel approach utilizes advanced computerized analysis techniques that make full use of the rich, high-resolution, volumetric data generated by modern CT scanners, to generate a more comprehensive and reliable assessment of aortic growth. VDM has the ability to significantly improve the speed and reliability of TAA growth analysis, facilitate the communication of aortic growth assessment between radiologists, care-providers and patients, and generate new biomarkers of disease progression that can be used to improve patient management decisions, and ultimately patient outcomes. In this grant effort, we propose to achieve the goals of this project through our close partnership between University of Michigan (UM) and Imbio, LLC investigators. Thus the Specific Aims of this Fast-Track proposal will develop a commercial VDM software application, including the product testing and data acquisition necessary for a FDA 510(k) application.